Kyocera could definitely buy amda and utilize the tech, but they don't have the sales force in place to capitalize. I would think Kyocera could manufacture and sell to different major ortho companies or license the tech while focusing on non-medical applications.
That said as you guys pointed out Zimmers needs are perfectly fulfilled with SiNi & strategic markets while Amedica gets access to Zimmers coffers and sales force. They are matched perfectly.
Zimmers already has experience with this exact scenario with Implex acquisition plus now has the benefits of being able to recognize potential pitfalls. It is these pitfalls that I believe caused Sonny to run SiNi through extensive testing because Zimmer would likely be very hesitant to pull the trigger otherwise.
News 
Market Data 
Discover 
